Graham Capital Management’s Travere Therapeutics TVTX Stock Holding History

Graham Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.4M	Buy	+446,696	New	+$19.8M	0.46%	39
2025 Q4	–	Sell	-466,998	Closed	-$11.2M	–	1592
2025 Q3	$11.2M	Buy	+466,998	New	+$8.78M	0.18%	64
2025 Q2	–	Sell	-379,900	Closed	-$6.81M	–	1635
2025 Q1	$6.81M	Buy	379,900 +362,285	+2,057%	+$7.35M	0.12%	93
2024 Q4	$307K	Buy	+17,615	New	+$312K	﹤0.01%	920
2023 Q4	–	Sell	-16,071	Closed	-$144K	–	1346
2023 Q3	$144K	Sell	16,071 -19,287	-55%	-$272K	﹤0.01%	906
2023 Q2	$543K	Buy	+35,358	New	+$643K	0.02%	535
2022 Q1	–	Sell	-7,791	Closed	-$241K	–	1024
2021 Q4	$241K	Buy	+7,791	New	+$219K	0.01%	396

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's TVTX Position: Q2 2026 in Review

Graham Capital Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 446,696 shares worth $25.4M. The stake represents 0.46% of the portfolio and ranks #39 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in TVTX as recently as Q3 2025.

Graham Capital Management first reported a position in TVTX in Q4 2021 and has held it in 7 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Graham Capital Management held 446,696 shares of Travere Therapeutics worth $25.4M as of Q2 2026.
Travere Therapeutics was a new Graham Capital Management position in Q2 2026.
Travere Therapeutics made up 0.46% of Graham Capital Management's portfolio in Q2 2026, its #39 holding.
Graham Capital Management first reported a position in Travere Therapeutics in Q4 2021 and has held it in 7 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.